This page contains information about prescription medications. According to the Russian regulatory requirements, this information can be available only for medical or pharmaceutical stuff.

Do you confirm that you are a medical of pharmaceutical specialist?

Report an adverse reaction
Main page

Projects by Generium

On immunity

Immunity is the ability of multicellular organisms to maintain the constancy of their macromolecular composition by removing products of foreign genetic information, which provides resistance to infectious agents and resistance to tumors.

There are 2 types of immune response: cellular and humoral. The result of the cellular response is the destruction of the foreign agent and the formation of cellular memory in case of re-infection. As a result of the humoral response, antibodies are formed - proteins that are specifically tuned against a particular pathological agent.

Today, modern laboratory diagnostic methods make it possible to fully assess the state of the immune system, as well as its response to the disease.

On immunity

TB at the COVID-19 era

Tuberculosis is an ancient enemy of humanity. Every fourth person on the planet is infected with tuberculosis. But the disease does not develop in everyone, but only in the absence or weakening of immunity.

Today, during the COVID-19 and HIV pandemics, there are a lot of people with reduced immunity. The number of victims of tuberculosis is also growing.

The attention of humanity today is focused on the COVID-19 pandemic. This is a huge and objective problem. But people continue to suffer from other, no less dangerous and socially significant diseases. Moreover, due to the coronavirus pandemic, people with other diseases often do not receive or receive less than necessary medical care.

TB at the COVID-19 era

Early access

GENERIUM has set up an early access program for Elizaria ® (INN - eculizumab) for the urgent treatment of patients with atypical hemolytic uremic syndrome (aHUS).

The program involves rapid (within 1 day) provision of patients with an established diagnosis in any region of the Russian Federation.

  • Were provided with the medication

    50 patients

  • Were saved from death

    26 children

Over the past year, about 50 patients in Russia with a newly diagnosed aHUS were provided with Elizaria by the charity company GENERIUM and received it throughout their hospital stay.

This allowed all new patients to be brought out of critical condition and saved from death this year, including 26 children.

After discharge from the hospital, patients were included in the Federal Register of Patients with Atypical Hemolytic-Uremic Syndrome and were provided at the expense of the Russian healthcare budget.

Early access